Embolx is an emerging commercial-stage medical device company in Silicon Valley developing microcatheters for arterial embolization procedures. Embolx is committed to dramatically improving the treatment of a variety of conditions including cancerous tumors, benign prostatic hyperplasia and uterine fibroids. The Sniper balloon occlusion microcatheter sets a new standard for precise embolic delivery and superior target filling by controlling pressure to direct blood flow while protecting non-target surrounding tissues.
Location: United States, California, Sunnyvale
Employees: 11-50
Founded date: 2013
Investors 4
| Date | Name | Website |
| 05.02.2021 | Life Scien... | lifescienc... |
| - | BayMed Ven... | baymedvp.c... |
| - | Generation... | generation... |
| - | Xandex Ven... | xandexvent... |
Mentions in press and media 2
| Date | Title | Description |
| 28.07.2025 | Embolx Launches Sniper G3: Revolutionizing Embolization with Enhanced Efficiency, Ease of Use, and Extended Shelf Life | SUNNYVALE, Calif., July 28, 2025 /PRNewswire/ -- Embolx, a leader in advanced microcatheters for targeted embolization procedures, today announced the release of its next-generation Sniper G3 Balloon Occlusion Microcatheter. This third iter... |
| 08.06.2021 | Embolx Launches Sniper into the European Market |